Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

Asthma control in adult patients treated with a combination of inhaled corticosteroids and long-acting beta-2 agonists: a prospective observational study

“…5,6 Patients are more likely to comply with LABA than with ICS mono therapy, but LABA monotherapy is not recom mended in the current guidelines of the Global Initiative for Asthma (GINA) 1 and the US Food and Drug Administration. 7 Therefore, the use of a combined inhaler allows patients to avoid out dated treatment and to improve compliance.…”

Health economics of asthma: assessing the value of asthma interventions

“…The cost-effectiveness of ICS therapy is widely accepted for those whom treatment with an ICS is appropriate. Further, the published literature indicates that ICS plus LABA combinations have favorable value for money (6)(7)(8). Leukotriene antagonists have more questionable value for money and this is consistent with their lower emphasis in GINA guidelines.…”

“…Stempel (6), Shih et al (7), and Shepherd et al (8) reviewed the cost-effectiveness evidence of single inhaler combination therapy for persistent asthma.…”

Demographic data in asthma clinical trials: A systematic review with implications for generalizing trial findings and tackling health disparities

“…Information was obtained from two peer-reviewed systematic reviews of randomized controlled trials which evaluated the clinical efficacy and safety of inhaled corticosteroids and long-acting betaagonists for asthma treatment in adults (Shepherd et al, 2008) and children (Main et al, 2008). The reviews were conducted to inform clinical guidance on asthma management that were being updated by the UK National Institute for Health and Clinical Excellence (UK National Institute for Health andClinical Excellence, 2008a, 2008b).…”

“…Interventions: five inhaled corticosteroids and two combination drugs (inhaled corticosteroid plus long-acting b-agonist) (Main et al, 2008;Shepherd et al, 2008), compared head-to-head in any combination or against a placebo, at any of their approved doses, with a minimum intervention duration of four weeks. Design: randomized controlled trials.…”